The Experts below are selected from a list of 68088 Experts worldwide ranked by ideXlab platform
Michael G Ison - One of the best experts on this subject based on the ideXlab platform.
-
use of the quantiferon tb gold interferon gamma Release Assay for screening transplant candidates a single center retrospective study
Transplant Infectious Disease, 2012Co-Authors: Nicole Theodoropoulos, Jasmine Rassiwala, Luke Preczewski, E Demayo, Valentina Stosor, Fanny Lanternier, Gwen Mcnatt, Michael G IsonAbstract:N. Theodoropoulos, F. Lanternier, J. Rassiwala, G. McNatt, L. Preczewski, E. DeMayo, V. Stosor, M.G. Ison. Use of the QuantiFERON-TB Gold interferon-gamma Release Assay for screening transplant candidates: a single-center retrospective study. Transpl Infect Dis 2011. All rights reserved Background. Tuberculosis (TB) reactivation is a rare but significant complication of organ transplantation, and screening of all transplant candidates for latent infection is recommended with either an interferon-γ Release Assay (IGRA) or tuberculin skin test (TST). Methods. After institutional review board approval, we retrospectively collected data to describe the yield of transplant candidate screening using the QuantiFERON-TB Gold (QFT) and QuantiFERON-TB Gold In-Tube (QFT-IT) Assays since the institution of TB screening in 2008 and the epidemiology of all cases of post-transplant TB in our institution since 2004. Results. A total of 2392 patients were screened with either the QFT or QFT-IT Assay through October 2009; 245 (10.2%) tested positive and 206 (8.6%) were indeterminate. Of those with positive results, 107 (43.7%) were foreign born and most of the remainder had prior TB exposures. Of the tests performed at a reference lab, 29% were indeterminate, whereas 14% were indeterminate using our in-house lab. The majority of indeterminate results were seen in liver transplant candidates (40.6% vs. 11.8% in non-liver candidates). Three of 694 (0.43%) screened patients who underwent transplantation developed TB post transplant. Conclusions. Post-transplant TB occurs at a low rate with universal IGRA-based candidate screening, which is comparable to studies using TST screening.
-
use of the quantiferon tb gold interferon gamma Release Assay for screening transplant candidates a single center retrospective study
Transplant Infectious Disease, 2012Co-Authors: Nicole Theodoropoulos, Jasmine Rassiwala, Luke Preczewski, E Demayo, Valentina Stosor, Fanny Lanternier, Gwen Mcnatt, Michael G IsonAbstract:N. Theodoropoulos, F. Lanternier, J. Rassiwala, G. McNatt, L. Preczewski, E. DeMayo, V. Stosor, M.G. Ison. Use of the QuantiFERON-TB Gold interferon-gamma Release Assay for screening transplant candidates: a single-center retrospective study. Transpl Infect Dis 2011. All rights reserved Background. Tuberculosis (TB) reactivation is a rare but significant complication of organ transplantation, and screening of all transplant candidates for latent infection is recommended with either an interferon-γ Release Assay (IGRA) or tuberculin skin test (TST). Methods. After institutional review board approval, we retrospectively collected data to describe the yield of transplant candidate screening using the QuantiFERON-TB Gold (QFT) and QuantiFERON-TB Gold In-Tube (QFT-IT) Assays since the institution of TB screening in 2008 and the epidemiology of all cases of post-transplant TB in our institution since 2004. Results. A total of 2392 patients were screened with either the QFT or QFT-IT Assay through October 2009; 245 (10.2%) tested positive and 206 (8.6%) were indeterminate. Of those with positive results, 107 (43.7%) were foreign born and most of the remainder had prior TB exposures. Of the tests performed at a reference lab, 29% were indeterminate, whereas 14% were indeterminate using our in-house lab. The majority of indeterminate results were seen in liver transplant candidates (40.6% vs. 11.8% in non-liver candidates). Three of 694 (0.43%) screened patients who underwent transplantation developed TB post transplant. Conclusions. Post-transplant TB occurs at a low rate with universal IGRA-based candidate screening, which is comparable to studies using TST screening.
Frank Seibold - One of the best experts on this subject based on the ideXlab platform.
-
comparison of interferon gamma Release Assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease
The American Journal of Gastroenterology, 2008Co-Authors: Alain M Schoepfer, Silvia Fallegger, Thomas Schaffer, Laurent P. Nicod, B Flogerzi, Stefan Mueller, Frank SeiboldAbstract:Comparison of Interferon-Gamma Release Assay Versus Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease
Nicole Theodoropoulos - One of the best experts on this subject based on the ideXlab platform.
-
use of the quantiferon tb gold interferon gamma Release Assay for screening transplant candidates a single center retrospective study
Transplant Infectious Disease, 2012Co-Authors: Nicole Theodoropoulos, Jasmine Rassiwala, Luke Preczewski, E Demayo, Valentina Stosor, Fanny Lanternier, Gwen Mcnatt, Michael G IsonAbstract:N. Theodoropoulos, F. Lanternier, J. Rassiwala, G. McNatt, L. Preczewski, E. DeMayo, V. Stosor, M.G. Ison. Use of the QuantiFERON-TB Gold interferon-gamma Release Assay for screening transplant candidates: a single-center retrospective study. Transpl Infect Dis 2011. All rights reserved Background. Tuberculosis (TB) reactivation is a rare but significant complication of organ transplantation, and screening of all transplant candidates for latent infection is recommended with either an interferon-γ Release Assay (IGRA) or tuberculin skin test (TST). Methods. After institutional review board approval, we retrospectively collected data to describe the yield of transplant candidate screening using the QuantiFERON-TB Gold (QFT) and QuantiFERON-TB Gold In-Tube (QFT-IT) Assays since the institution of TB screening in 2008 and the epidemiology of all cases of post-transplant TB in our institution since 2004. Results. A total of 2392 patients were screened with either the QFT or QFT-IT Assay through October 2009; 245 (10.2%) tested positive and 206 (8.6%) were indeterminate. Of those with positive results, 107 (43.7%) were foreign born and most of the remainder had prior TB exposures. Of the tests performed at a reference lab, 29% were indeterminate, whereas 14% were indeterminate using our in-house lab. The majority of indeterminate results were seen in liver transplant candidates (40.6% vs. 11.8% in non-liver candidates). Three of 694 (0.43%) screened patients who underwent transplantation developed TB post transplant. Conclusions. Post-transplant TB occurs at a low rate with universal IGRA-based candidate screening, which is comparable to studies using TST screening.
-
use of the quantiferon tb gold interferon gamma Release Assay for screening transplant candidates a single center retrospective study
Transplant Infectious Disease, 2012Co-Authors: Nicole Theodoropoulos, Jasmine Rassiwala, Luke Preczewski, E Demayo, Valentina Stosor, Fanny Lanternier, Gwen Mcnatt, Michael G IsonAbstract:N. Theodoropoulos, F. Lanternier, J. Rassiwala, G. McNatt, L. Preczewski, E. DeMayo, V. Stosor, M.G. Ison. Use of the QuantiFERON-TB Gold interferon-gamma Release Assay for screening transplant candidates: a single-center retrospective study. Transpl Infect Dis 2011. All rights reserved Background. Tuberculosis (TB) reactivation is a rare but significant complication of organ transplantation, and screening of all transplant candidates for latent infection is recommended with either an interferon-γ Release Assay (IGRA) or tuberculin skin test (TST). Methods. After institutional review board approval, we retrospectively collected data to describe the yield of transplant candidate screening using the QuantiFERON-TB Gold (QFT) and QuantiFERON-TB Gold In-Tube (QFT-IT) Assays since the institution of TB screening in 2008 and the epidemiology of all cases of post-transplant TB in our institution since 2004. Results. A total of 2392 patients were screened with either the QFT or QFT-IT Assay through October 2009; 245 (10.2%) tested positive and 206 (8.6%) were indeterminate. Of those with positive results, 107 (43.7%) were foreign born and most of the remainder had prior TB exposures. Of the tests performed at a reference lab, 29% were indeterminate, whereas 14% were indeterminate using our in-house lab. The majority of indeterminate results were seen in liver transplant candidates (40.6% vs. 11.8% in non-liver candidates). Three of 694 (0.43%) screened patients who underwent transplantation developed TB post transplant. Conclusions. Post-transplant TB occurs at a low rate with universal IGRA-based candidate screening, which is comparable to studies using TST screening.
Alain M Schoepfer - One of the best experts on this subject based on the ideXlab platform.
-
comparison of interferon gamma Release Assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease
The American Journal of Gastroenterology, 2008Co-Authors: Alain M Schoepfer, Silvia Fallegger, Thomas Schaffer, Laurent P. Nicod, B Flogerzi, Stefan Mueller, Frank SeiboldAbstract:Comparison of Interferon-Gamma Release Assay Versus Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease
Young Ae Kang - One of the best experts on this subject based on the ideXlab platform.
-
comparison of the tuberculin skin test and interferon γ Release Assay for the diagnosis of latent tuberculosis infection before kidney transplantation
Infection, 2013Co-Authors: Gyeong Seo Jung, Joon Chang, Young Ae KangAbstract:Purpose The evaluation of latent tuberculosis infection (LTBI) is recommended before kidney transplantation. The interferon-γ Release Assay has been reported to be more specific than the tuberculin skin test (TST) for detecting LTBI. We compared the TST and QuantiFERON-TB Gold In-Tube test (QFT-GIT) for the screening for LTBI and determined the agreement between the two tests in renal transplant recipients before transplantation.
-
performance of the tuberculin skin test and interferon γ Release Assay for detection of tuberculosis infection in immunocompromised patients in a bcg vaccinated population
BMC Infectious Diseases, 2009Co-Authors: Ji Ye Jung, Yoe Wun Yoon, Byung Hoon Park, Jin Wook Moon, Moo Suk Park, Joon Chang, Young Ae KangAbstract:Background Interferon-γ Release Assay (IGRA) may improve diagnostic accuracy for latent tuberculosis infection (LTBI). This study compared the performance of the tuberculin skin test (TST) with that of IGRA for the diagnosis of LTBI in immunocompromised patients in an intermediate TB burden country where BCG vaccination is mandatory.
